

## Ocular Therapeutix Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 26-Apr-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 12

Product Portfolio Financials..... 14

Product Portfolio Drugs..... 15

[Return to Table of Contents](#)

# Ocular Therapeutix Inc

## COMPANY OVERVIEW

Company Name	Ocular Therapeutix Inc
Parent Company Name	Ocular Therapeutix Inc
Website	http://www.ocutx.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	2
Number of Patents as Owner	1
Number of Patents as Third Party	0
Number of Deals	0
Key Indications	Glaucoma, Conjunctivitis, Ocular inflammation, Allergic conjunctivitis, Ocular pain, Retinopathy, Xerophthalmia, Angle closure glaucoma, Ocular hypertension, Ocular infection, Open angle glaucoma
Key Target-based Actions	Calcineurin inhibitor, DNA gyrase inhibitor, Glucocorticoid agonist, Prostanoid receptor agonist, Topoisomerase IV inhibitor, VEGF receptor antagonist
Key Technologies	Sustained release formulation, Small molecule therapeutic, Ophthalmic gel formulation, Drug implant, Microparticle formulation, Ophthalmic formulation, PEGylated formulation, Peptide, Antibiotic, Biological therapeutic, Lipid, Ophthalmic drug implant

## COMPANY PROFILE

### SUMMARY

Ocular Therapeutix Inc (formerly I-Therapeutix), founded in November 2006, aims to develop and commercialize ophthalmic therapeutic products and ocular drug delivery vehicles using its hydrogel technology. In September 2009, I-Therapeutix changed its name to Ocular Therapeutix.

### FINANCIAL

In July 2014, Ocular priced an IPO of 5 million shares at \$13 per share. Underwriters were granted an overallotment option to purchase up to 0.75 million additional shares. Shares were expected to be traded on the NASDAQ Global Market under the ticker symbol 'OCUL' on July 25, 2014. In August 2014, the company raised gross and net proceeds of approximately \$74.8 and \$66.5 million, respectively through the IPO of 5.75 million shares including the full exercise of the over-allotment option.

In June 2013, Ocular secured additional financing.

In January 2013, Ocular raised \$23.8 million from a series D extension round of financing.

In February 2011, Ocular raised \$14 million from a series D financing round.

## COMPANY FINANCIALS

### SHARE INFORMATION

Close Price (USD)	25.36
Change (USD)	-1.12 (-4.23%)
Previous Close Price (USD)	26.48

[Return to Table of Contents](#)



Volume	156,547
52-Week High (USD)	44.19
52-Week Low (USD)	11.90
Date	24-Apr-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	21,333,507
Current Market Capitalization	543,109,506
EPS (Date Reported)	-2.69026

### STOCK PERFORMANCE



### MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Fidelity Select Biotechnology Portfolio	Mutual Fund	United States	453,168	2.12	277,640	1.58	28-Feb-2015

[Return to Table of Contents](#)

American Funds Insurance Series Global Small Capitalization	Mutual Fund	England	377,500	1.76	377,500	1	31-Mar-2015
Hartford Healthcare Fund	Mutual Fund	United States	154,882	0.72	7,380	0.05	28-Feb-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	127,192	0.59	69,970	1.22	31-Mar-2015
iShares Russell 2000 ETF	Mutual Fund	United States	100,510	0.47	3,095	0.03	31-Mar-2015
DWS Biotech	Mutual Fund	Germany	96,356	0.45	0	0	28-Feb-2015
Fidelity Advisor Biotechnology Fund	Mutual Fund	United States	93,730	0.44	58,659	1.67	28-Feb-2015
Fidelity Trend Fund	Mutual Fund	United States	78,254	0.37	18,300	0.31	28-Feb-2015
AST Small-Cap Growth Opportunities Portfolio	Mutual Fund	United States	67,466	0.32	-42,296	-0.39	28-Feb-2015
Met Inv. Ser. Trust Blackrock Large-Cap Core Portf	Mutual Fund	United States	64,800	0.3	0	0	28-Feb-2015
Lindstrom (Richard L)	Individual Investor	United States	62,498	0.29	24,620	0.65	27-Feb-2015
Satuit Capital Management, LLC	Investment Advisor	United States	51,600	0.24	-42,900	-0.45	28-Feb-2015
Satuit Capital U.S. Emerging Companies Fund	Mutual Fund	United States	51,600	0.24	-42,900	-0.45	28-Feb-2015
iShares Russell 2000 Growth ETF	Mutual Fund	United States	41,755	0.19	3,292	0.09	31-Mar-2015
USAA Science & Technology Fund	Mutual Fund	United States	34,460	0.16	1,120	0.03	28-Feb-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	30,466	0.14	24,236	3.89	28-Feb-2015
Principal SmallCap Blend Fund	Mutual Fund	United States	18,690	0.09	-23,630	-0.56	31-Mar-2015
VALIC Co I Small Cap Aggressive Growth Fund	Mutual Fund	United States	20,923	0.1	-17,877	-0.46	28-Feb-2015
iShares Micro-Cap ETF	Mutual Fund	United States	15,258	0.07	369	0.02	31-Mar-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	16,922	0.08	0	0	28-Feb-2015


[Return to Table of Contents](#)





## FINANCIAL PERFORMANCE

### Sales and Income



	2012	2013	2014		
<b>Sales (USD M)</b>	0.01	0	0.772		
<b>Operating Income (USD M)</b>	-13.671	-12.903	-27.094		
<b>Net Income (USD M)</b>	-14.128	-13.344	-28.659		

### Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	0.505	-7.547	-7.954
2014 Q3	0.143	-6.776	-7.294
2014 Q2	0.097	-5.946	-6.397
2014 Q1	0.027	-6.825	-7.014
2013 Q2	0	-2.989	-3.099
2013 Q1	0	-3.06	-3.208

[Return to Table of Contents](#)

## BALANCE SHEET

### Assets (USD M)

	2012	2013	2014		
Cash & Short Term Investments	23.854	17.505	74.828		
Inventories - Total	0	0	0.133		
Current Assets - Total	24.262	18.014	76.183		
Property, Plant And Equipment - Net	0.785	0.904	1.782		
Other Assets - Total	0.01	0	0		
Total Assets	25.285	19.146	78.193		

### Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	0.583	0.545	1.316		
Short Term Debt & Current Portion Of Long Term Debt	1.806	3.624	1.354		
Current Liabilities - Total	3.475	3.342	5.874		
Long Term Debt	2.259	0.651	13.511		
Deferred Taxes	0	0			
Other Liabilities	0.339	0.281	0.112		
Total Liabilities	6.073	4.274	19.497		

### Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	0		
Preferred Stock	65.823	74.344	0		
Common Stock	0	0	0.002		
Total Liabilities & Shareholders' Equity	25.285	19.146	78.193		

## FORECASTS

[Return to Table of Contents](#)

## EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.43	-1.43	-1.41
31-Dec-2016	-1.59	-1.51	-1.39
31-Dec-2017	-1.47	-1.22	-1.19

## Other Forecasts


Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-30.9	4.2
31-Dec-2016			-39.77	11.57
31-Dec-2017			-39.33	29.5

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	4	1	5
Inflammatory disease	2	0	2
Neurological disease	1	0	1
Immune disorder	0	1	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	1
No Development Reported	2

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
-------------------	---------	-----

[Return to Table of Contents](#)

## Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	1	15
Inflammatory disease	0	5
Neurological disease	0	3
Infectious disease	0	1
Surgical procedure	0	1

## Trials by Phase

Phase	Ongoing	All
Phase 3	0	2
Phase 2	1	6
Phase 1	0	1
Phase not specified	0	6

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*


Indication	As Owner	As Third Party	Total
Ocular disease	2	0	2
Infectious disease	1	0	1
Inflammatory disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.


[Return to Table of Contents](#)

PRODUCT PORTFOLIO FINANCIALS

DRUG SALES AND FORECASTS



Drug Sales as a Share of the Total Sales 2016



[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix

<b>Drug Name</b>	dexamethasone (punctum plug, ocular inflammation), Ocular Therapeutix
<b>Key Synonyms</b>	dexamethasone
<b>Originator Company</b>	Ocular Therapeutix Inc
<b>Active Companies</b>	Ocular Therapeutix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Xerophthalmia, Allergic conjunctivitis, Ocular inflammation, Ocular pain
<b>Target-based Actions</b>	Glucocorticoid agonist
<b>Other Actions</b>	Ophthalmological corticosteroid, Steroidal anti-inflammatory, Anti-inflammatory, Analgesic
<b>Technologies</b>	Sustained release formulation, Ophthalmic formulation, Ophthalmic drug implant, Small molecule therapeutic
<b>Last Change Date</b>	16-Apr-2015

### travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix

<b>Drug Name</b>	travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix
<b>Key Synonyms</b>	travoprost
<b>Originator Company</b>	Ocular Therapeutix Inc
<b>Active Companies</b>	Ocular Therapeutix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Glaucoma
<b>Target-based Actions</b>	Prostanoid receptor agonist
<b>Other Actions</b>	PGF2 alpha agonist, Antiglaucoma agent
<b>Technologies</b>	Lipid, Drug implant, Sustained release formulation, Microparticle formulation, Small molecule therapeutic, Ophthalmic gel formulation
<b>Last Change Date</b>	11-Mar-2015

[Return to Table of Contents](#)



**moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix**

<b>Drug Name</b>	moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix
<b>Key Synonyms</b>	moxifloxacin
<b>Originator Company</b>	Ocular Therapeutix Inc
<b>Active Companies</b>	Ocular Therapeutix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Conjunctivitis
<b>Target-based Actions</b>	Topoisomerase IV inhibitor, DNA gyrase inhibitor
<b>Other Actions</b>	Ophthalmological antibacterial, Bacterial nucleic acid synthesis inhibitor
<b>Technologies</b>	PEGylated formulation, Drug implant, Sustained release formulation, Antibiotic, Microparticle formulation, Small molecule therapeutic, Ophthalmic gel formulation
<b>Last Change Date</b>	22-Dec-2014

**anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix**

<b>Drug Name</b>	anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix
<b>Key Synonyms</b>	
<b>Originator Company</b>	Ocular Therapeutix Inc
<b>Active Companies</b>	Ocular Therapeutix Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Retinopathy
<b>Target-based Actions</b>	VEGF receptor antagonist
<b>Other Actions</b>	
<b>Technologies</b>	PEGylated formulation, Sustained release formulation, Ophthalmic formulation, Small molecule therapeutic, Peptide
<b>Last Change Date</b>	13-Nov-2014

[Return to Table of Contents](#)





This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

